Published in Cancer on July 12, 2011
Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75
The association between statin medication and progression after surgery for localized renal cell carcinoma. J Urol (2013) 1.41
Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol (2013) 1.20
CKD and the risk of incident cancer. J Am Soc Nephrol (2014) 1.08
Effects of statins on the prognosis of local and locally advanced renal cell carcinoma following nephrectomy. Mol Clin Oncol (2012) 0.80
Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urol Oncol (2014) 0.79
Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials. Br J Clin Pharmacol (2014) 0.77
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet (1994) 40.72
Prospective study of alcohol consumption and risk of coronary disease in men. Lancet (1991) 8.64
Test of the National Death Index. Am J Epidemiol (1984) 8.46
The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer (2005) 8.19
Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ (2010) 5.19
Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer (1997) 3.85
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol (2008) 3.33
Statin use and the risk of 10 cancers. Epidemiology (2007) 3.17
The risk of cancer in users of statins. J Clin Oncol (2004) 3.01
HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia (2002) 2.89
Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology (2007) 2.73
Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf (2008) 2.43
Contemporary epidemiology of renal cell cancer. Cancer J (2008) 2.40
Statin use and cancer risk in the General Practice Research Database. Br J Cancer (2004) 2.34
Statins and cancer: A systematic review and meta-analysis. Eur J Cancer (2008) 2.15
Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. Urology (2008) 1.66
The role of statins in cancer therapy. Oncologist (2006) 1.46
The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med (2003) 1.23
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res (2004) 1.16
Intakes of fruits, vegetables, vitamins A, C, and E, and carotenoids and risk of renal cell cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.16
Lipid-lowering drugs. Cell Mol Life Sci (2006) 1.14
Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res (2008) 1.13
Type 2 diabetes and the risk of renal cell cancer in women. Diabetes Care (2011) 1.05
Diverse effects of statins on angiogenesis: new therapeutic avenues. Pharmacotherapy (2010) 1.01
Total fluid intake and use of individual beverages and risk of renal cell cancer in two large cohorts. Cancer Epidemiol Biomarkers Prev (2006) 1.01
Reproductive factors and risk of renal cell cancer: the Nurses' Health Study. Am J Epidemiol (2009) 0.98
Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance. Clin Exp Immunol (2010) 0.84
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA (2011) 7.61
Marital status and survival in patients with cancer. J Clin Oncol (2013) 5.82
Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol (2011) 4.60
Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation (2003) 3.50
Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol (2006) 3.41
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med (2011) 2.34
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res (2011) 2.27
Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA (2013) 2.26
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol (2006) 2.23
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol (2009) 2.23
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol (2010) 2.18
Comparison of methods to account for implausible reporting of energy intake in epidemiologic studies. Am J Epidemiol (2015) 2.11
Dramatic amplification of a rice transposable element during recent domestication. Proc Natl Acad Sci U S A (2006) 2.07
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int (2011) 2.07
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Carbohydrate intake, glycemic index, glycemic load, and dietary fiber in relation to risk of stroke in women. Am J Epidemiol (2005) 2.03
Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol (2011) 2.02
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol (2012) 2.00
Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol (2013) 1.95
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol (2012) 1.86
Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer (2011) 1.85
Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology (2010) 1.83
Fat, protein, and meat consumption and renal cell cancer risk: a pooled analysis of 13 prospective studies. J Natl Cancer Inst (2008) 1.81
Factors associated with the adoption of minimally invasive radical prostatectomy in the United States. J Urol (2012) 1.78
Dietary fat and cholesterol and the risk of cardiovascular disease among women with type 2 diabetes. Am J Clin Nutr (2004) 1.75
Effects of marital transitions on changes in dietary and other health behaviours in US women. Int J Epidemiol (2004) 1.74
Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol (2014) 1.74
Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU Int (2013) 1.73
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology (2010) 1.68
The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica (2006) 1.67
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
Predicted plasma 25-hydroxyvitamin D and risk of renal cell cancer. J Natl Cancer Inst (2013) 1.60
Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. J Natl Cancer Inst (2007) 1.57
Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer (2010) 1.52
Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer (2010) 1.52
Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin Cancer Res (2006) 1.45
Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys (2010) 1.44
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med (2014) 1.43
Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer (2014) 1.41
Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. J Natl Cancer Inst (2007) 1.37
Red meat consumption during adolescence among premenopausal women and risk of breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.36
Pazopanib: Clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol (2010) 1.36
Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol (2010) 1.29
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer (2011) 1.26
A prospective study of smoking and risk of breast cancer in young adult women. Cancer Epidemiol Biomarkers Prev (2004) 1.25
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol (2012) 1.24
Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin Proc (2005) 1.22
Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol (2010) 1.22
Adolescent diet in relation to breast cancer risk among premenopausal women. Cancer Epidemiol Biomarkers Prev (2010) 1.19
Dietary patterns and the risk of breast cancer. Ann Epidemiol (2005) 1.15
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol (2007) 1.13
Intakes of fruit, vegetables, and carotenoids and renal cell cancer risk: a pooled analysis of 13 prospective studies. Cancer Epidemiol Biomarkers Prev (2009) 1.12
Intake of fiber and nuts during adolescence and incidence of proliferative benign breast disease. Cancer Causes Control (2010) 1.11
Testicular cancer. J Natl Compr Canc Netw (2012) 1.11
Patterns of care for radical prostatectomy in the United States from 2003 to 2005. J Urol (2008) 1.08
Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med (2014) 1.07
Adolescent diet and incidence of proliferative benign breast disease. Cancer Epidemiol Biomarkers Prev (2003) 1.07
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer (2012) 1.07
Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer (2012) 1.07
Kidney cancer. J Natl Compr Canc Netw (2011) 1.06
Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension (2010) 1.05
Type 2 diabetes and the risk of renal cell cancer in women. Diabetes Care (2011) 1.05
Risk of bilateral renal cell cancer. J Clin Oncol (2009) 1.04
Dietary flavonols and flavonol-rich foods intake and the risk of breast cancer. Int J Cancer (2005) 1.03
The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep (2012) 1.03
Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J (2013) 1.00
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol (2011) 1.00
Non-clear cell renal cancer: features and medical management. J Natl Compr Canc Netw (2009) 1.00
Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys (2011) 1.00
Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate (2011) 1.00
Treatment selection for patients with metastatic renal cell carcinoma. Cancer (2009) 0.99
Elicitation of health state utilities in metastatic renal cell carcinoma. Curr Med Res Opin (2010) 0.99
Reproductive factors and risk of renal cell cancer: the Nurses' Health Study. Am J Epidemiol (2009) 0.98
Kidney cancer, version 2.2014. J Natl Compr Canc Netw (2014) 0.98
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer (2014) 0.98
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer (2008) 0.97
Dietary acrylamide intake and risk of premenopausal breast cancer. Am J Epidemiol (2009) 0.97
Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies. Int J Cancer (2013) 0.96
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol (2013) 0.95
Intakes of coffee, tea, milk, soda and juice and renal cell cancer in a pooled analysis of 13 prospective studies. Int J Cancer (2007) 0.95
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med (2014) 0.95
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw (2011) 0.94
Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med (2013) 0.94
Differential expression of caveolin-1 in renal neoplasms. Cancer (2007) 0.93